+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Central Nervous System Biomarkers Market by Type (Genomic Biomarkers, Metabolomic Biomarkers, Proteomic Biomarkers), Disease Indication (Neurodegenerative Diseases, Neurodevelopmental Disorders, Psychotic Disorders), Technology, Application, End-User - Global Forecast 2025-2030- Product Image
Central Nervous System Biomarkers Market by Type (Genomic Biomarkers, Metabolomic Biomarkers, Proteomic Biomarkers), Disease Indication (Neurodegenerative Diseases, Neurodevelopmental Disorders, Psychotic Disorders), Technology, Application, End-User - Global Forecast 2025-2030- Product Image
Sale

Central Nervous System Biomarkers Market by Type (Genomic Biomarkers, Metabolomic Biomarkers, Proteomic Biomarkers), Disease Indication (Neurodegenerative Diseases, Neurodevelopmental Disorders, Psychotic Disorders), Technology, Application, End-User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 193 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6010785
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Central nervous system biomarkers are redefining neurological healthcare by enabling earlier detection, targeted therapies, and more precise patient stratification. As life sciences leaders seek future-ready solutions, understanding this evolving market's structural and regulatory landscape is key.

Market Snapshot: Central Nervous System Biomarkers Market

The Central Nervous System Biomarkers Market grew from USD 4.80 billion in 2024 to USD 5.19 billion in 2025. It is expected to continue growing at a CAGR of 7.72%, reaching USD 7.50 billion by 2030. Market momentum is being driven by increased investment in biomarker research, cross-sector partnerships, and technological advances supporting both research and clinical adoption across Americas, EMEA, and Asia-Pacific.

Scope & Segmentation

This report delivers a comprehensive analysis of the central nervous system biomarkers landscape, with segmentation across biomarker types, disease indications, technologies, applications, end-users, regions, and leading commercial players.

  • Biomarker Types: Genomic, metabolomic, and proteomic biomarkers.
  • Disease Indications: Neurodegenerative diseases, neurodevelopmental disorders, and psychotic disorders.
  • Technology Platforms: Immunoassays (ELISA, Western Blot), mass spectrometry (gas and liquid chromatography-coupled), next-generation sequencing (targeted and whole genome sequencing).
  • Applications: Diagnosis and therapeutics, drug discovery and development, personalized medicine, prognosis, research and development.
  • End-Users: Academic research institutes, healthcare providers, pharmaceutical companies.
  • Regions & Sub-Regions: Americas (United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including United Kingdom, Germany, France, Russia, UAE, South Africa, and others), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, and others).
  • Leading Companies: A selection of major stakeholders includes Abbott Laboratories, Abbvie Inc., Acumen Pharmaceuticals Inc., ADx NeuroSciences NV, Agilent Technologies, Altoida, Becton Dickinson, BioMérieux SA, Bruker Corporation, C2N Diagnostics, and others across the value chain.

Key Takeaways for Decision-Makers

  • Emerging central nervous system biomarkers are strengthening the foundation for precision medicine, supporting targeted therapy development and improved patient selection.
  • Recent advances in high-throughput analytical technologies enable scalable, multi-omics biomarker detection, facilitating implementation in both academic and clinical environments.
  • Close collaboration among industry, academia, and clinical research centers is accelerating biomarker validation and transfer to routine healthcare practice.
  • Stakeholders are placing higher priority on platforms that integrate genomic, proteomic, and metabolic data, addressing unmet needs in complex neurological conditions.
  • Access to reliable biomarker assays and advanced analytical systems is essential for maintaining clinical trial momentum and securing regulatory acceptance in diversified markets.
  • Regional nuances, from funding approaches in the Americas to technology adoption rates in Asia-Pacific, require tailored go-to-market strategies and ongoing market monitoring.

Tariff Policy Shifts: Supply Chain & Strategic Considerations

Anticipated changes to United States tariff structures from 2025 will directly affect central nervous system biomarker market participants reliant on imported assay kits, reagents, and specialized instruments. Operational costs are set to rise, prompting many organizations to evaluate domestic sourcing, technology transfer partnerships, and targeted supply-chain digitization to ensure continuity and quality control. These adjustments will likely prioritize investment in high-impact biomarker projects, with risk management strategies becoming increasingly important to mitigate procurement disruptions and adapt to evolving policy landscapes.

Central Nervous System Biomarkers Market: Methodology & Data Sources

This analysis synthesizes primary insights from interviews with senior executives and researchers, combined with systematic secondary research encompassing literature, regulatory documents, and competitive intelligence. Data consistency was cross-validated, with qualitative and quantitative patterns mapped to emerging trends, segmentation, and company activity. Adherence to industry best practices and data triangulation underpin the analytical rigor of the findings.

Why This Report Matters

  • Supports strategic investment and development decisions with actionable intelligence tailored to the evolving central nervous system biomarkers market.
  • Offers practical guidance on navigating regulatory change, technology adoption, and regional dynamics in biomarker research and commercialization.
  • Enables benchmarking of innovation pipelines and partnership models among leading industry players and academic collaborators.

Conclusion

Central nervous system biomarkers continue to shape the future of neurological medicine by driving advancements in diagnosis and therapy. Decision-makers equipped with robust insights from this report are positioned to seize emerging opportunities and navigate complex market dynamics confidently.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Integration of digital twin modeling with multi-omics CNS biomarker discovery for personalized therapy selection
5.2. Adoption of blood-brain barrier permeability assays to validate peripheral CNS biomarker candidates in clinical trials
5.3. Use of exosomal microRNA signatures in cerebrospinal fluid as prognostic indicators for early Alzheimer's detection
5.4. Commercial development of PET radioligands targeting synaptic density as quantitative biomarkers in neurodegenerative research
5.5. Implementation of artificial intelligence algorithms to analyze longitudinal biomarker data from CNS disease progression studies
5.6. Collaboration between pharmaceutical companies and diagnostic firms to co-develop companion diagnostics for CNS oncology treatments
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Central Nervous System Biomarkers Market, by Type
8.1. Introduction
8.2. Genomic Biomarkers
8.3. Metabolomic Biomarkers
8.4. Proteomic Biomarkers
9. Central Nervous System Biomarkers Market, by Disease Indication
9.1. Introduction
9.2. Neurodegenerative Diseases
9.3. Neurodevelopmental Disorders
9.4. Psychotic Disorders
10. Central Nervous System Biomarkers Market, by Technology
10.1. Introduction
10.2. Immunoassay
10.2.1. ELISA
10.2.2. Western Blot
10.3. Mass Spectrometry
10.3.1. Gas Chromatography Coupled
10.3.2. Liquid Chromatography Coupled
10.4. Next-Generation Sequencing
10.4.1. Targeted Sequencing
10.4.2. Whole Genome Sequencing
11. Central Nervous System Biomarkers Market, by Application
11.1. Introduction
11.2. Diagnosis & Therapeutics
11.3. Drug Discovery & Development
11.4. Personalized Medicine
11.5. Prognosis
11.6. Research & Development
12. Central Nervous System Biomarkers Market, by End-User
12.1. Introduction
12.2. Academic Research Institutes
12.3. Healthcare Providers
12.4. Pharmaceutical Companies
13. Americas Central Nervous System Biomarkers Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Central Nervous System Biomarkers Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Central Nervous System Biomarkers Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Abbott Laboratories
16.3.2. Abbvie Inc.
16.3.3. Acumen Pharmaceuticals Inc.
16.3.4. ADx NeuroSciences NV
16.3.5. Agilent Technologies, Inc.
16.3.6. Altoida
16.3.7. Becton, Dickinson and Company
16.3.8. Bio-Rad Laboratories, Inc.
16.3.9. BioMérieux SA
16.3.10. Bruker Corporation
16.3.11. C2N Diagnostics, LLC
16.3.12. Cerevance, LLC
16.3.13. Charles River Laboratories International, Inc.
16.3.14. Eli Lilly and Co.
16.3.15. F. Hoffmann-La Roche AG
16.3.16. Invicro LLC
16.3.17. Johnson & Johnson Services Inc.
16.3.18. Laboratory Corporation of America Holdings
16.3.19. Mediford Corporation
16.3.20. Merck & Co., Inc.
16.3.21. Myriad Genetics, Inc.
16.3.22. Neurotrack Technologies, Inc.
16.3.23. Novartis AG
16.3.24. Qiagen N.V.
16.3.25. Quanterix Corporation
16.3.26. Sanofi SA
16.3.27. Shimadzu Corporation
16.3.28. Siemens Healthineers
16.3.29. SynapCell
16.3.30. Thermo Fisher Scientific Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 10. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET: RESEARCHAI
FIGURE 26. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET: RESEARCHSTATISTICS
FIGURE 27. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET: RESEARCHCONTACTS
FIGURE 28. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY GENOMIC BIOMARKERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY GENOMIC BIOMARKERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY METABOLOMIC BIOMARKERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY METABOLOMIC BIOMARKERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PROTEOMIC BIOMARKERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PROTEOMIC BIOMARKERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEURODEVELOPMENTAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEURODEVELOPMENTAL DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PSYCHOTIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PSYCHOTIC DISORDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY ELISA, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY ELISA, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY WESTERN BLOT, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY WESTERN BLOT, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY GAS CHROMATOGRAPHY COUPLED, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY GAS CHROMATOGRAPHY COUPLED, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY LIQUID CHROMATOGRAPHY COUPLED, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY LIQUID CHROMATOGRAPHY COUPLED, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DIAGNOSIS & THERAPEUTICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DIAGNOSIS & THERAPEUTICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PERSONALIZED MEDICINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PROGNOSIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PROGNOSIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY RESEARCH & DEVELOPMENT, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY HEALTHCARE PROVIDERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY HEALTHCARE PROVIDERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 72. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 107. CANADA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 108. CANADA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 109. CANADA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 110. CANADA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 111. CANADA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 112. CANADA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 113. CANADA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
TABLE 114. CANADA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2025-2030 (USD MILLION)
TABLE 115. CANADA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
TABLE 116. CANADA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2025-2030 (USD MILLION)
TABLE 117. CANADA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 118. CANADA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2025-2030 (USD MILLION)
TABLE 119. CANADA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 120. CANADA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 121. CANADA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 122. CANADA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 123. MEXICO CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 124. MEXICO CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 125. MEXICO CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 126. MEXICO CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 127. MEXICO CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 128. MEXICO CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 129. MEXICO CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
TABLE 130. MEXICO CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2025-2030 (USD MILLION)
TABLE 131. MEXICO CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
TABLE 132. MEXICO CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2025-2030 (USD MILLION)
TABLE 133. MEXICO CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 134. MEXICO CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2025-2030 (USD MILLION)
TABLE 135. MEXICO CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 136. MEXICO CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 137. MEXICO CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 138. MEXICO CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 139. BRAZIL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 140. BRAZIL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 141. BRAZIL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 142. BRAZIL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 143. BRAZIL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 144. BRAZIL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 145. BRAZIL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
TABLE 146. BRAZIL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2025-2030 (USD MILLION)
TABLE 147. BRAZIL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
TABLE 148. BRAZIL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2025-2030 (USD MILLION)
TABLE 149. BRAZIL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 150. BRAZIL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2025-2030 (USD MILLION)
TABLE 151. BRAZIL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 152. BRAZIL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 153. BRAZIL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 154. BRAZIL CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 155. ARGENTINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 156. ARGENTINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 157. ARGENTINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 158. ARGENTINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 159. ARGENTINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 160. ARGENTINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 161. ARGENTINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
TABLE 162. ARGENTINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2025-2030 (USD MILLION)
TABLE 163. ARGENTINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
TABLE 164. ARGENTINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2025-2030 (USD MILLION)
TABLE 165. ARGENTINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 166. ARGENTINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2025-2030 (USD MILLION)
TABLE 167. ARGENTINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 168. ARGENTINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 169. ARGENTINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 170. ARGENTINA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 177. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
TABLE 178. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2025-2030 (USD MILLION)
TABLE 179. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
TABLE 180. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2025-2030 (USD MILLION)
TABLE 181. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 182. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2025-2030 (USD MILLION)
TABLE 183. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 184. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 185. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 186. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 187. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 188. EUROPE, MIDDLE EAST & AFRICA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 190. UNITED KINGDOM CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 191. UNITED KINGDOM CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 192. UNITED KINGDOM CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 193. UNITED KINGDOM CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 194. UNITED KINGDOM CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 195. UNITED KINGDOM CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
TABLE 196. UNITED KINGDOM CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2025-2030 (USD MILLION)
TABLE 197. UNITED KINGDOM CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
TABLE 198. UNITED KINGDOM CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2025-2030 (USD MILLION)
TABLE 199. UNITED KINGDOM CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 200. UNITED KINGDOM CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2025-2030 (USD MILLION)
TABLE 201. UNITED KINGDOM CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 202. UNITED KINGDOM CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 203. UNITED KINGDOM CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 204. UNITED KINGDOM CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 205. GERMANY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 206. GERMANY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 207. GERMANY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 208. GERMANY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 209. GERMANY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 210. GERMANY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 211. GERMANY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
TABLE 212. GERMANY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2025-2030 (USD MILLION)
TABLE 213. GERMANY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
TABLE 214. GERMANY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2025-2030 (USD MILLION)
TABLE 215. GERMANY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 216. GERMANY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2025-2030 (USD MILLION)
TABLE 217. GERMANY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 218. GERMANY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 219. GERMANY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 220. GERMANY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 221. FRANCE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 222. FRANCE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 223. FRANCE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 224. FRANCE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 225. FRANCE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 226. FRANCE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 227. FRANCE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
TABLE 228. FRANCE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2025-2030 (USD MILLION)
TABLE 229. FRANCE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
TABLE 230. FRANCE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2025-2030 (USD MILLION)
TABLE 231. FRANCE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 232. FRANCE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2025-2030 (USD MILLION)
TABLE 233. FRANCE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 234. FRANCE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 235. FRANCE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 236. FRANCE CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 237. RUSSIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 238. RUSSIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 239. RUSSIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 240. RUSSIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 241. RUSSIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 242. RUSSIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 243. RUSSIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
TABLE 244. RUSSIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2025-2030 (USD MILLION)
TABLE 245. RUSSIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
TABLE 246. RUSSIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2025-2030 (USD MILLION)
TABLE 247. RUSSIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 248. RUSSIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2025-2030 (USD MILLION)
TABLE 249. RUSSIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 250. RUSSIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 251. RUSSIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 252. RUSSIA CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 253. ITALY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 254. ITALY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 255. ITALY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 256. ITALY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 257. ITALY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 258. ITALY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 259. ITALY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
TABLE 260. ITALY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2025-2030 (USD MILLION)
TABLE 261. ITALY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
TABLE 262. ITALY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2025-2030 (USD MILLION)
TABLE 263. ITALY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 264. ITALY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2025-2030 (USD MILLION)
TABLE 265. ITALY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 266. ITALY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 267. ITALY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 268. ITALY CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 269. SPAIN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 270. SPAIN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 271. SPAIN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 272. SPAIN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 273. SPAIN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 274. SPAIN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 275. SPAIN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
TABLE 276. SPAIN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2025-2030 (USD MILLION)
TABLE 277. SPAIN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024 (USD MILLION)
TABLE 278. SPAIN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2025-2030 (USD MILLION)
TABLE 279. SPAIN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2024 (USD MILLION)
TABLE 280. SPAIN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2025-2030 (USD MILLION)
TABLE 281. SPAIN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 282. SPAIN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 283. SPAIN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
TABLE 284. SPAIN CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
TABLE 285. UNITED ARAB EMIRATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
TABLE 286. UNITED ARAB EMIRATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
TABLE 287. UNITED ARAB EMIRATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2018-2024 (USD MILLION)
TABLE 288. UNITED ARAB EMIRATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY DISEASE INDICATION, 2025-2030 (USD MILLION)
TABLE 289. UNITED ARAB EMIRATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
TABLE 290. UNITED ARAB EMIRATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
TABLE 291. UNITED ARAB EMIRATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2018-2024 (USD MILLION)
TABLE 292. UNITED ARAB EMIRATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY IMMUNOASSAY, 2025-2030 (USD MILLION)
TABLE 293. UNITED ARAB EMIRATES CENTRAL NERVOUS SYSTEM BIOMARKERS MARKET SIZE, BY MASS SPECTROMETRY, 2018-2024

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Central Nervous System Biomarkers market report include:
  • Abbott Laboratories
  • Abbvie Inc.
  • Acumen Pharmaceuticals Inc.
  • ADx NeuroSciences NV
  • Agilent Technologies, Inc.
  • Altoida
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • BioMérieux SA
  • Bruker Corporation
  • C2N Diagnostics, LLC
  • Cerevance, LLC
  • Charles River Laboratories International, Inc.
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche AG
  • Invicro LLC
  • Johnson & Johnson Services Inc.
  • Laboratory Corporation of America Holdings
  • Mediford Corporation
  • Merck & Co., Inc.
  • Myriad Genetics, Inc.
  • Neurotrack Technologies, Inc.
  • Novartis AG
  • Qiagen N.V.
  • Quanterix Corporation
  • Sanofi SA
  • Shimadzu Corporation
  • Siemens Healthineers
  • SynapCell
  • Thermo Fisher Scientific Inc.

Table Information

Report AttributeDetails
No. of Pages193
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 5.19 Billion
Forecasted Market Value ( USD ) by 2030 $ 7.5 Billion
Compound Annual Growth Rate7.7%
Regions CoveredGlobal
No. of Companies Mentioned31

Related Topics

Related Reports

Central Nervous System Biomarkers Market Report 2025 - Product Image

Central Nervous System Biomarkers Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Central Nervous System Biomarkers - Global Strategic Business Report - Product Image

Central Nervous System Biomarkers - Global Strategic Business Report

  • Report
  • 376 Pages
  • Global
From
Central Nervous System Biomarker Market Report: Trends, Forecast and Competitive Analysis to 2030 - Product Image

Central Nervous System Biomarker Market Report: Trends, Forecast and Competitive Analysis to 2030

  • Report
  • 150 Pages
  • Global
From
Global Central Nervous System Biomarkers - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030) - Product Image

Global Central Nervous System Biomarkers - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

  • Report
  • 115 Pages
  • Global
From
Biomarker Test Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Biomarker Test Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From

About the CNS Marker Market

Biomarkers are biological molecules that can be used to measure and monitor the progression of a disease or condition. The Central Nervous System (CNS) Marker market is a subset of the biomarker market that focuses on the development of biomarkers for neurological diseases and disorders. CNS Markers are used to diagnose, monitor, and treat neurological diseases and disorders, such as Alzheimer’s, Parkinson’s, and Multiple Sclerosis. They are also used to measure the effectiveness of treatments and to predict the risk of developing neurological diseases. CNS Markers are typically proteins, peptides, or metabolites that are found in the cerebrospinal fluid, blood, or other bodily fluids. They can be used to detect the presence of a neurological disorder, to monitor the progression of the disorder, and to measure the effectiveness of treatments. Some companies in the CNS Marker market include Bio-Rad Laboratories, Bio-Techne, and Abcam. Other companies include Bio-Techne, Abcam, and Bio-Rad Laboratories. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.